Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ataxin-8 is a protein encoded by the ATXN8 gene in humans. It is associated with spinocerebellar ataxia type 8 (SCA8), a neurodegenerative disorder. SCA8 is caused by a CTG/CAG trinucleotide repeat expansion on chromosome 13q21, with two genes spanning the repeat and expressed in opposite directions: ATXN8 (encoding a nearly pure polyglutamine protein in the CAG direction) and ATXN8OS (a noncoding transcript in the other direction). The pathogenic protein can form nuclear inclusions and is believed to contribute to neurodegeneration[1][5]. There is no evidence that Ataxin-8 directly constitutes a drug target (e.g., receptor, enzyme, transporter) or that drugs directly interact with it for therapeutic purposes, although variation in the ATXN8 gene can play a disease role in spinocerebellar ataxia and potentially other neurological disorders[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ataxin-8 (ATXN8).